FindTrial
Sign In

Abexinostat

DRUG7 trials

Sponsors

Rahul Aggarwal, Xynomic Pharmaceuticals, Inc., Memorial Sloan Kettering Cancer Center

Conditions

Diffuse Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)Follicular LymphomaLocally Advanced MelanomaLocally Advanced Solid NeoplasmLymphoma, FollicularMantle Cell LymphomaMetastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
CompletedNCT03590054
Rahul AggarwalLocally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma +18
Start: 2018-08-20End: 2023-11-30Updated: 2024-03-22
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
CompletedNCT03939182
Memorial Sloan Kettering Cancer CenterDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Start: 2019-05-29End: 2025-04-22Updated: 2025-04-25
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
Active, not recruitingNCT04024696
Xynomic Pharmaceuticals, Inc.Non Hodgkin Lymphoma
Start: 2020-01-08End: 2025-11-30Updated: 2025-04-10

Phase 2

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Active, not recruitingNCT03600441
Xynomic Pharmaceuticals, Inc.Follicular Lymphoma
Start: 2018-08-27End: 2029-12-31Target: 139Updated: 2025-04-10
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Active, not recruitingNCT03934567
Xynomic Pharmaceuticals, Inc.Lymphoma, Follicular
Start: 2020-04-22End: 2025-10-30Updated: 2025-04-10
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
RecruitingNCT03936153
Xynomic Pharmaceuticals, Inc.Diffuse Large B-cell Lymphoma (DLBCL)
Start: 2020-01-20End: 2027-08-31Target: 170Updated: 2025-04-10

Phase 3

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RecruitingNCT03592472
Xynomic Pharmaceuticals, Inc.Renal Cell Carcinoma
Start: 2018-07-17End: 2028-06-30Target: 413Updated: 2025-04-13

Related Papers

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
2026-04-27
Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.
2025-05-30
A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma.
Journal of Clinical Oncology2024-06-012 citations
Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.
Journal of Clinical Oncology2022-06-012 citations
Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
Journal of Clinical Oncology2019-05-206 citations
RENAVIV: A randomized phase III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma.
Journal of Clinical Oncology2019-03-0110 citations